Sox HC. Quality of life and guidelines for PSA screening. N Engl J Med. 2012 Aug;367(7):669- -71.Sox , Harold C. . (2012) Quality of Life and Guidelines for PSA Screening. New England Journal of Medicine 367 :7, 669-671 ${xml_link: 10.1056%2FNEJMe1207165}...
"PSA screening for more than 40 percent of men 75 or older is inappropriate," said study author Scott Eggener, MD, assistant professor of surgery at the University of Chicago Medicine. "Selective screening is reasonable to consider for the healthiest men over age 75, but for the large majori...
PSA screening to detect the most common male cancer is among the most heated topics in men’s health. It involves a simple blood test for elevated levels of a protein that may signal cancer but also can be caused by less serious prostate problems. It can find cancer that frequently doesn’...
The authors point out that three randomized controlled trials provided Level 1 evidence that regular PSA screening of men 50 to 74 years of age of average risk reduced metastasis and prostate cancer death at 16 to 22 years of follow-up. “The best available evidence specifically for Black m...
The benefits of screening with the prostate-specific antigen (PSA) test are outweighed by the harms for most men. Prostate cancer never becomes clinically significant in a patient's lifetime in a considerable proportion of men with prostate cancer detected with the PSA test. They will receive ...
Further evidence is needed to inform value-based genetic testing strategies for implementation in practice.Similar content being viewed by others Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups Article Open access 18 December ...
Prostate cancer screening: Canadian Guidelines [21]Canadian Urological Association, 2011YesProstate cancer screening should be offered to all men 50 years of age with at least a 10-year life expectancy (LE: 1) Strong consideration should be given to discontinuing PSA screening for Canadian men over...
The CACA Guidelines for Holistic Integrative Management of Prostate Cancer includes epidemiology, screening and diagnosis, treatment for localized PC, diagnosis and treatment of PC recurrence after radical prostatectomy, management of metastatic PC, traditional Chinese medicine diagnosis and treatment of PC,...
The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or Western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8 times higher than in 2000. Ther...
This is in part due to a discrepancy between the two large randomized controlled trials comparing PSA screening to usual care. The European Randomized Study of Screening for Prostate Cancer (ERSPC) found a survival benefit to screening, while the United States Prostate, Lung, Colorectal, and ...